Case Study

This case involves a 68-year-old male patient with long-segment non-dysplastic Barrett’s esophagus and high anxiety stemming from the loss of his brother to esophageal adenocarcinoma.

“TissueCypher helped us to reassure [the patient] that he was making the right decision, lowered his anxiety, and gave him a high confidence level”

Case details

  • BMI 28 (overweight)
  • Chronic GERD for 30 years
  • Daily PPI:  Rabeprazole 40 mg
  • Non-smoker
  • Brother has EAC (T3N1Mx)
  • Has been in surveillance program for NDBE every 3-5 years
Case Study

This case involves a 68-year-old male patient with long-segment non-dysplastic Barrett’s esophagus and high anxiety stemming from the loss of his brother to esophageal adenocarcinoma.

“TissueCypher helped us to reassure [the patient] that he was making the right decision, lowered his anxiety, and gave him a high confidence level”

Case details

  • BMI 28 (overweight)
  • Chronic GERD for 30 years
  • Daily PPI:  Rabeprazole 40 mg
  • Non-smoker
  • Brother has EAC (T3N1Mx)
  • Has been in surveillance program for NDBE every 3-5 years
Case Study

This case involves a 68-year-old male patient with long-segment non-dysplastic Barrett’s esophagus and high anxiety stemming from the loss of his brother to esophageal adenocarcinoma.

“TissueCypher helped us to reassure [the patient] that he was making the right decision, lowered his anxiety, and gave him a high confidence level”

Case details

  • BMI 28 (overweight)
  • Chronic GERD for 30 years
  • Daily PPI:  Rabeprazole 40 mg
  • Non-smoker
  • Brother has EAC (T3N1Mx)
  • Has been in surveillance program for NDBE every 3-5 years
Dr. Charles Loewe: Case 2

Clinical risk factors

A 68-year-old male patient with a 30-year history of GERD and high anxiety secondary to his brother  who has esophageal adenocarcinoma (EAC) without having any prior symptoms of GERD.

RELEVANT MEDICAL HISTORY
  • BMI 28 (overweight)
  • Chronic GERD for 30 years
  • Daily PPI:  Rabeprazole 40 mg
  • Non-smoker
ADDITIONAL CONSIDERATIONS
  • Brother has EAC (T3N1Mx)
  • Has been in surveillance program for NDBE every 3-5 years

Endoscopic findings

The endoscopy confirmed the presence of long-segment non-dysplasatic Barrett's esophagus by both traditional pathology and WATS3D.

Lower esophagus:
  • BE segment: C3M3
  • 2 cm hiatal hernia​
  • Non-dysplastic pathology
  • WATS3D-confirmed NDBE
Traditional Management:
  • Clinical profile: High risk due to family history
  • Treatment recommendation: 1-year surveillance or Endoscopic Eradication Therapy (EET)

TissueCypher results

Dr. Loewe and the patient were considering short interval surveillance or eradication therapy. The high-risk TissueCypher result tipped the scales in favor of proceeding to EET.  

  • Risk class: High
  • Risk score: 6.4
  • 5-year risk of progression: 12%

TissueCypher-guided management

  • Change in management: Upstaged to EET

“TissueCypher helped us to reassure [the patient] that he was making the right decision, lowered his anxiety, and gave him a high confidence level.”

Charles Loewe, MD